Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data

被引:10
作者
Laurini, Greta Santi [1 ]
Montanaro, Nicola [2 ]
Motola, Domenico [1 ]
机构
[1] Alma Mater Studiorum Univ Bologna, Dept Med & Surg Sci, Unit Pharmacol, I-40126 Bologna, Italy
[2] Alma Mater Studiorum Univ Bologna, I-40126 Bologna, Italy
关键词
molnupiravir; COVID-19; safety; pharmacovigilance; FAERS; ADVERSE DRUG-REACTIONS;
D O I
10.3390/jcm12010034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Concerns have been raised about the actual benefit and safety of molnupiravir, a new antiviral treatment for coronavirus disease 2019 (COVID-19). In order to provide additional evidence to support its use, we aimed to evaluate the real safety profile based on post-marketing pharmacovigilance data. Molnupiravir safety data were captured from the FDA Adverse Event Reporting System (FAERS). We performed a descriptive analysis of the baseline demographic characteristics of patients who experienced at least one adverse drug reaction (ADRs) related to molnupiravir, and then evaluated those most frequently reported. As of 31 March 2022, 612 reports of ADRs related to molnupiravir were submitted to the FDA, 301 (49.18%) were related to females and 281 (45.92%) to males. Most reports (524; 85.62%) were submitted by healthcare professionals and 345 (56.37%) concerned serious outcomes. The most common reported ADRs were diarrhoea (57; 4.51%), rash (36; 2.85), nausea (29; 2.30%), and COVID-19 pneumonia (22; 1.74%). The most frequent adverse reactions reported with molnupiravir in the U.S. post-marketing experience are consistent with the safety evaluation of the antiviral medicine. Even if no evident safety concerns emerged, an unexpectedly high rate of serious adverse reactions together with a few cases of potential new adverse reactions occurred.
引用
收藏
页数:8
相关论文
共 39 条
  • [1] Small-Molecule Antiviral β-D-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance
    Agostini, Maria L.
    Pruijssers, Andrea J.
    Chappell, James D.
    Gribble, Jennifer
    Lu, Xiaotao
    Andres, Erica L.
    Bluemling, Gregory R.
    Lockwood, Mark A.
    Sheahan, Timothy P.
    Sims, Amy C.
    Natchus, Michael G.
    Saindane, Manohar
    Kolykhalov, Alexander A.
    Painter, George R.
    Baric, Ralph S.
    Denison, Mark R.
    [J]. JOURNAL OF VIROLOGY, 2019, 93 (24)
  • [2] Alimohamadi Yousef, 2020, J Prev Med Hyg, V61, pE304, DOI 10.15167/2421-4248/jpmh2020.61.3.1530
  • [3] Factors affecting the development of adverse drug reactions (Review article)
    Alomar, Muaed Jamal
    [J]. SAUDI PHARMACEUTICAL JOURNAL, 2014, 22 (02) : 83 - 94
  • [4] [Anonymous], UPTODATE COVID 19 CL
  • [5] MERS-CoV infection: Mind the public knowledge gap
    Bawazir, Amen
    Al-Mazroo, Eman
    Jradi, Hoda
    Ahmed, Anwar
    Badri, Motasim
    [J]. JOURNAL OF INFECTION AND PUBLIC HEALTH, 2018, 11 (01) : 89 - 93
  • [6] Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
    Bernal, A. Jayk
    da Silva, M. M. Gomes
    Musungaie, D. B.
    Kovalchuk, E.
    Gonzalez, A.
    Delos Reyes, V
    Martin-Quiros, A.
    Caraco, Y.
    Williams-Diaz, A.
    Brown, M. L.
    Du, J.
    Pedley, A.
    Assaid, C.
    Strizki, J.
    Grobler, J. A.
    Shamsuddin, H. H.
    Tipping, R.
    Wan, H.
    Paschke, A.
    Butterton, J. R.
    Johnson, M. G.
    De Anda, C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (06) : 509 - 520
  • [7] Molnupiravir's authorisation was premature Regulatory decisions fall short of the wise stewardship required during a pandemic
    Brophy, James
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2022, 376
  • [8] Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
    Chen, Rita E.
    Zhang, Xianwen
    Case, James Brett
    Winkler, Emma S.
    Liu, Yang
    VanBlargan, Laura A.
    Liu, Jianying
    Errico, John M.
    Xie, Xuping
    Suryadevara, Naveenchandra
    Gilchuk, Pavlo
    Zost, Seth J.
    Tahan, Stephen
    Droit, Lindsay
    Turner, Jackson S.
    Kim, Wooseob
    Schmitz, Aaron J.
    Thapa, Mahima
    Wang, David
    Boon, Adrianus C. M.
    Presti, Rachel M.
    O'Halloran, Jane A.
    Kim, Alfred H. J.
    Deepak, Parakkal
    Pinto, Dora
    Fremont, Daved H.
    Crowe, James E., Jr.
    Corti, Davide
    Virgin, Herbert W.
    Ellebedy, Ali H.
    Shi, Pei-Yong
    Diamond, Michael S.
    [J]. NATURE MEDICINE, 2021, 27 (04) : 717 - 726
  • [9] Dougan M, 2022, medRxiv, DOI [10.1101/2022.03.10.22272100, 10.1101/2022.03.10.22272100v1, DOI 10.1101/2022.03.10.22272100V1, 10.1101/2022.03.10.22272100, DOI 10.1101/2022.03.10.22272100]
  • [10] Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
    Dougan, M.
    Nirula, A.
    Azizad, M.
    Mocherla, B.
    Gottlieb, R. L.
    Chen, P.
    Hebert, C.
    Perry, R.
    Boscia, J.
    Heller, B.
    Morris, J.
    Crystal, C.
    Igbinadolor, A.
    Huhn, G.
    Cardona, J.
    Shawa, I
    Kumar, P.
    Adams, A. C.
    Van Naarden, J.
    Custer, K. L.
    Durante, M.
    Oakley, G.
    Schade, A. E.
    Holzer, T. R.
    Ebert, P. J.
    Higgs, R. E.
    Kallewaard, N. L.
    Sabo, J.
    Patel, D. R.
    Dabora, M. C.
    Klekotka, P.
    Shen, L.
    Skovronsky, D. M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15) : 1382 - 1392